tumor-infiltrating lymphocytes + ipilimumab + nivolumab + interleukin-2

This personalized autologous cellular immunotherapy protocol is being developed by Inge Marie Svane and colleagues at the Center for Cancer Immune Therapy, Herlev Hospital. The therapy involves adoptive cell therapy (ACT) where tumor-infiltrating lymphocytes (TILs) are harvested from a patient's own tumor tissue, expanded ex vivo to generate a large population of tumor-reactive T cells, and then reinfused back into the patient. In this specific Phase 1/2 clinical trial regimen, the TIL infusion is combined with the immune checkpoint inhibitors ipilimumab (an anti-CTLA-4 monoclonal antibody) and nivolumab (an anti-PD-1 monoclonal antibody) to potentially overcome tumor-induced immunosuppression and enhance the clinical efficacy of the T cells. The protocol also includes a lymphodepleting preconditioning regimen of cyclophosphamide and fludarabine, followed by low-dose subcutaneous interleukin-2 (IL-2) to support the survival and proliferation of the infused lymphocytes in vivo.

Other names

TIL therapyAdoptive T cell therapyACTTIL + Checkpoint Inhibitors